Julie V Philley1, Richard J Wallace2, Jeana L Benwill3, Varsha Taskar4, Barbara A Brown-Elliott5, Foram Thakkar4, Timothy R Aksamit6, David E Griffith4. 1. Department of Medicine, University of Texas Health Science Center at Tyler, Tyler, TX. Electronic address: Julie.Philley@uthct.edu. 2. Department of Medicine, University of Texas Health Science Center at Tyler, Tyler, TX; Mycobacteria/Nocardia Research Laboratory, University of Texas Health Science Center at Tyler, Tyler, TX; Department of Microbiology, University of Texas Health Science Center at Tyler, Tyler, TX. 3. Department of Medicine, University of Texas Health Science Center at Tyler, Tyler, TX; Mycobacteria/Nocardia Research Laboratory, University of Texas Health Science Center at Tyler, Tyler, TX. 4. Department of Medicine, University of Texas Health Science Center at Tyler, Tyler, TX. 5. Mycobacteria/Nocardia Research Laboratory, University of Texas Health Science Center at Tyler, Tyler, TX; Department of Microbiology, University of Texas Health Science Center at Tyler, Tyler, TX. 6. Department of Medicine, Mayo Clinic, Rochester, MN.
Abstract
BACKGROUND: Bedaquiline is an oral antimycobacterial agent belonging to a new class of drugs called diarylquinolines. It has low equivalent minimal inhibitory concentrations for Mycobacterium tuberculosis and nontuberculous mycobacterial (NTM) lung disease, especially Mycobacterium avium complex (MAC) and Mycobacterium abscessus (Mab). Bedaquiline appears to be effective for the treatment of multidrug-resistant TB but has not been tested clinically for NTM disease. METHODS: We describe a case series of off-label use of bedaquiline for treatment failure lung disease caused by MAC or Mab. Only patients whose insurance would pay for the drug were included. Fifteen adult patients were selected, but only 10 (six MAC, four Mab) could obtain bedaquiline. The 10 patients had been treated for 1 to 8 years, and all were on treatment at the start of bedaquiline therapy. Eighty percent had macrolide-resistant isolates (eight of 10). The patients were treated with the same bedaquiline dosage as that used in TB trials and received the best available companion drugs (mean, 5.0 drugs). All patients completed 6 months of therapy and remain on bedaquiline. RESULTS: Common side effects included nausea (60%), arthralgias (40%), and anorexia and subjective fever (30%). No abnormal ECG findings were observed with a mean corrected QT interval lengthening of 2.4 milliseconds at 6 months. After 6 months of therapy, 60% of patients (six of 10) had a microbiologic response, with 50% (five of 10) having one or more negative cultures. CONCLUSIONS: This small preliminary report demonstrates potential clinical and microbiologic activity of bedaquiline in patients with advanced MAC or Mab lung disease but the findings require confirmation with larger studies.
BACKGROUND:Bedaquiline is an oral antimycobacterial agent belonging to a new class of drugs called diarylquinolines. It has low equivalent minimal inhibitory concentrations for Mycobacterium tuberculosis and nontuberculous mycobacterial (NTM) lung disease, especially Mycobacterium avium complex (MAC) and Mycobacterium abscessus (Mab). Bedaquiline appears to be effective for the treatment of multidrug-resistant TB but has not been tested clinically for NTM disease. METHODS: We describe a case series of off-label use of bedaquiline for treatment failure lung disease caused by MAC or Mab. Only patients whose insurance would pay for the drug were included. Fifteen adult patients were selected, but only 10 (six MAC, four Mab) could obtain bedaquiline. The 10 patients had been treated for 1 to 8 years, and all were on treatment at the start of bedaquiline therapy. Eighty percent had macrolide-resistant isolates (eight of 10). The patients were treated with the same bedaquiline dosage as that used in TB trials and received the best available companion drugs (mean, 5.0 drugs). All patients completed 6 months of therapy and remain on bedaquiline. RESULTS: Common side effects included nausea (60%), arthralgias (40%), and anorexia and subjective fever (30%). No abnormal ECG findings were observed with a mean corrected QT interval lengthening of 2.4 milliseconds at 6 months. After 6 months of therapy, 60% of patients (six of 10) had a microbiologic response, with 50% (five of 10) having one or more negative cultures. CONCLUSIONS: This small preliminary report demonstrates potential clinical and microbiologic activity of bedaquiline in patients with advanced MAC or Mab lung disease but the findings require confirmation with larger studies.
Authors: T Prammananan; P Sander; B A Brown; K Frischkorn; G O Onyi; Y Zhang; E C Böttger; R J Wallace Journal: J Infect Dis Date: 1998-06 Impact factor: 5.226
Authors: David E Griffith; Barbara A Brown-Elliott; Brett Langsjoen; Yansheng Zhang; Xi Pan; William Girard; Kenwyn Nelson; James Caccitolo; Julio Alvarez; Sara Shepherd; Rebecca Wilson; Edward A Graviss; Richard J Wallace Journal: Am J Respir Crit Care Med Date: 2006-07-20 Impact factor: 21.405
Authors: Anna Milano; Maria Rosalia Pasca; Roberta Provvedi; Anna Paola Lucarelli; Giulia Manina; Ana Luisa de Jesus Lopes Ribeiro; Riccardo Manganelli; Giovanna Riccardi Journal: Tuberculosis (Edinb) Date: 2008-10-11 Impact factor: 3.131
Authors: Kenneth N Olivier; Pamela A Shaw; Tanya S Glaser; Darshana Bhattacharyya; Michelle Fleshner; Carmen C Brewer; Christopher K Zalewski; Les R Folio; Jenifer R Siegelman; Shamira Shallom; In Kwon Park; Elizabeth P Sampaio; Adrian M Zelazny; Steven M Holland; D Rebecca Prevots Journal: Ann Am Thorac Soc Date: 2014-01
Authors: Richard D Kim; David E Greenberg; Mary E Ehrmantraut; Shireen V Guide; Li Ding; Yvonne Shea; Margaret R Brown; Milica Chernick; Wendy K Steagall; Connie G Glasgow; JingPing Lin; Clara Jolley; Lynn Sorbara; Mark Raffeld; Suvimol Hill; Nilo Avila; Vandana Sachdev; Lisa A Barnhart; Victoria L Anderson; Reginald Claypool; Dianne M Hilligoss; Mary Garofalo; Alan Fitzgerald; Sandra Anaya-O'Brien; Dirk Darnell; Rosamma DeCastro; Heather M Menning; Stacy M Ricklefs; Stephen F Porcella; Kenneth N Olivier; Joel Moss; Steven M Holland Journal: Am J Respir Crit Care Med Date: 2008-08-14 Impact factor: 21.405
Authors: Simone Mok; Margaret M Hannan; Lars Nölke; Patrick Stapleton; Niamh O'Sullivan; Philip Murphy; Anne Marie McLaughlin; Eleanor McNamara; Margaret M Fitzgibbon; Thomas R Rogers Journal: Antimicrob Agents Chemother Date: 2019-08-23 Impact factor: 5.191
Authors: Arthur W Baker; Eileen K Maziarz; Sarah S Lewis; Jason E Stout; Deverick J Anderson; Peter K Smith; Jacob N Schroder; Mani A Daneshmand; Barbara D Alexander; Richard J Wallace; Daniel J Sexton; Cameron R Wolfe Journal: Clin Infect Dis Date: 2021-04-08 Impact factor: 9.079
Authors: David C Alexander; Ravikiran Vasireddy; Sruthi Vasireddy; Julie V Philley; Barbara A Brown-Elliott; Benjamin J Perry; David E Griffith; Jeana L Benwill; Andrew D S Cameron; Richard J Wallace Journal: J Clin Microbiol Date: 2016-12-07 Impact factor: 5.948
Authors: Barbara A Brown-Elliott; Julie V Philley; David E Griffith; Foram Thakkar; Richard J Wallace Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191